Cargando…
Health crisis: What opportunities for clinical drug research?()
The COVID-19 pandemic led to the deployment of an unprecedented academic and industrial research effort, the sometimes redundant nature of which is regrettable, as is the lack of both national and international management. However, it must be noted that during this crisis, regulatory procedures were...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673948/ https://www.ncbi.nlm.nih.gov/pubmed/34973823 http://dx.doi.org/10.1016/j.therap.2021.12.008 |
_version_ | 1784615545992118272 |
---|---|
author | Deplanque, Dominique Cviklinski, Stanislas Bardou, Marc Ader, Florence Blanchard, Hervé Barthélémy, Philippe David, Isabelle D’Ortenzio, Eric Espérou, Hélène Launay, Odile Lazarevic, Milan Lechat, Philippe Lethiec, Françoise Levy, Yves Pérol, David Rage, Virginie Roustit, Matthieu Thabut, Gabriel |
author_facet | Deplanque, Dominique Cviklinski, Stanislas Bardou, Marc Ader, Florence Blanchard, Hervé Barthélémy, Philippe David, Isabelle D’Ortenzio, Eric Espérou, Hélène Launay, Odile Lazarevic, Milan Lechat, Philippe Lethiec, Françoise Levy, Yves Pérol, David Rage, Virginie Roustit, Matthieu Thabut, Gabriel |
author_sort | Deplanque, Dominique |
collection | PubMed |
description | The COVID-19 pandemic led to the deployment of an unprecedented academic and industrial research effort, the sometimes redundant nature of which is regrettable, as is the lack of both national and international management. However, it must be noted that during this crisis, regulatory procedures were adapted and certain obstacles in the organisation of clinical research were partly removed to contribute to the deployment of trials as close as possible to patients and to facilitate monitoring and control procedures. The digitisation of certain processes and the decentralisation of certain activities were implemented under the cover of a mobilisation of the authorities and all institutional, academic and industrial players. While in the UK, the optimisation of resources through a single platform trial has made it possible to demonstrate or invalidate the efficacy of many treatments, in France the health crisis has highlighted the fragility of the organisation of clinical research, in particular a lack of coordination and funding, difficulties in implementing studies and a certain reluctance to share data. However, the crisis has also revealed the adaptability of the various stakeholders and has led to the improvement of several processes useful for the deployment of therapeutic innovation. Let us hope that the lessons learned during this crisis will allow for greater efficiency in the event of a new pandemic and, above all, that the progress made will continue to apply to all future clinical research activities. |
format | Online Article Text |
id | pubmed-8673948 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86739482021-12-16 Health crisis: What opportunities for clinical drug research?() Deplanque, Dominique Cviklinski, Stanislas Bardou, Marc Ader, Florence Blanchard, Hervé Barthélémy, Philippe David, Isabelle D’Ortenzio, Eric Espérou, Hélène Launay, Odile Lazarevic, Milan Lechat, Philippe Lethiec, Françoise Levy, Yves Pérol, David Rage, Virginie Roustit, Matthieu Thabut, Gabriel Therapie Giens Workshops 2021/Health technologies The COVID-19 pandemic led to the deployment of an unprecedented academic and industrial research effort, the sometimes redundant nature of which is regrettable, as is the lack of both national and international management. However, it must be noted that during this crisis, regulatory procedures were adapted and certain obstacles in the organisation of clinical research were partly removed to contribute to the deployment of trials as close as possible to patients and to facilitate monitoring and control procedures. The digitisation of certain processes and the decentralisation of certain activities were implemented under the cover of a mobilisation of the authorities and all institutional, academic and industrial players. While in the UK, the optimisation of resources through a single platform trial has made it possible to demonstrate or invalidate the efficacy of many treatments, in France the health crisis has highlighted the fragility of the organisation of clinical research, in particular a lack of coordination and funding, difficulties in implementing studies and a certain reluctance to share data. However, the crisis has also revealed the adaptability of the various stakeholders and has led to the improvement of several processes useful for the deployment of therapeutic innovation. Let us hope that the lessons learned during this crisis will allow for greater efficiency in the event of a new pandemic and, above all, that the progress made will continue to apply to all future clinical research activities. Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. 2022 2021-12-16 /pmc/articles/PMC8673948/ /pubmed/34973823 http://dx.doi.org/10.1016/j.therap.2021.12.008 Text en © 2021 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Giens Workshops 2021/Health technologies Deplanque, Dominique Cviklinski, Stanislas Bardou, Marc Ader, Florence Blanchard, Hervé Barthélémy, Philippe David, Isabelle D’Ortenzio, Eric Espérou, Hélène Launay, Odile Lazarevic, Milan Lechat, Philippe Lethiec, Françoise Levy, Yves Pérol, David Rage, Virginie Roustit, Matthieu Thabut, Gabriel Health crisis: What opportunities for clinical drug research?() |
title | Health crisis: What opportunities for clinical drug research?() |
title_full | Health crisis: What opportunities for clinical drug research?() |
title_fullStr | Health crisis: What opportunities for clinical drug research?() |
title_full_unstemmed | Health crisis: What opportunities for clinical drug research?() |
title_short | Health crisis: What opportunities for clinical drug research?() |
title_sort | health crisis: what opportunities for clinical drug research?() |
topic | Giens Workshops 2021/Health technologies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8673948/ https://www.ncbi.nlm.nih.gov/pubmed/34973823 http://dx.doi.org/10.1016/j.therap.2021.12.008 |
work_keys_str_mv | AT deplanquedominique healthcrisiswhatopportunitiesforclinicaldrugresearch AT cviklinskistanislas healthcrisiswhatopportunitiesforclinicaldrugresearch AT bardoumarc healthcrisiswhatopportunitiesforclinicaldrugresearch AT aderflorence healthcrisiswhatopportunitiesforclinicaldrugresearch AT blanchardherve healthcrisiswhatopportunitiesforclinicaldrugresearch AT barthelemyphilippe healthcrisiswhatopportunitiesforclinicaldrugresearch AT davidisabelle healthcrisiswhatopportunitiesforclinicaldrugresearch AT dortenzioeric healthcrisiswhatopportunitiesforclinicaldrugresearch AT esperouhelene healthcrisiswhatopportunitiesforclinicaldrugresearch AT launayodile healthcrisiswhatopportunitiesforclinicaldrugresearch AT lazarevicmilan healthcrisiswhatopportunitiesforclinicaldrugresearch AT lechatphilippe healthcrisiswhatopportunitiesforclinicaldrugresearch AT lethiecfrancoise healthcrisiswhatopportunitiesforclinicaldrugresearch AT levyyves healthcrisiswhatopportunitiesforclinicaldrugresearch AT peroldavid healthcrisiswhatopportunitiesforclinicaldrugresearch AT ragevirginie healthcrisiswhatopportunitiesforclinicaldrugresearch AT roustitmatthieu healthcrisiswhatopportunitiesforclinicaldrugresearch AT thabutgabriel healthcrisiswhatopportunitiesforclinicaldrugresearch |